Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chlortetracycline is a broad-spectrum tetracycline antibiotic and was the first of its class to be discovered. It acts as a bacteriostatic agent by inhibiting bacterial protein synthesis. The drug binds to the 30S ribosomal subunit of bacteria, preventing aminoacyl-tRNA from attaching to the A site of the ribosome, thereby blocking peptide chain elongation and ultimately inhibiting bacterial growth and reproduction[1][6]. Chlortetracycline is primarily used in veterinary medicine for treating conjunctivitis in cats, dogs, and horses; infected wounds in cattle, sheep, and pigs; as well as respiratory tract infections in calves, pigs, and chickens[3]. In humans it is mainly used topically for eye infections or as part of combination creams for infected allergic dermatitis[2][3]. Its oral bioavailability is about 25-30% with peak plasma concentration reached within three hours after administration[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlortetracycline.